Thermo Fisher Scientific (Life Technologies) Reagents and Consumable Materials for Cell Therapy Manufacturing
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institutes of Health Clinical Center, specifically the Center for Cellular Engineering, intends to award a firm-fixed-price contract to Thermo Fisher Scientific for reagents and consumable materials. These supplies, which include various mediums, buffers, and beads, are essential for the manufacture of cell-based therapies for patients in clinical trials. The procurement is being pursued as a sole-source acquisition because the specific materials have already been validated and approved by Quality Assurance for use under FDA-regulated current Good Manufacturing Practice conditions. The agency asserts that substituting these materials would lead to significant costs, time delays, and potential disruptions to patient treatment due to the need for extensive requalification of manufacturing processes. While the government intends to proceed with Thermo Fisher Scientific, other responsible sources may submit capability statements by August 20, 2026. These submissions must demonstrate the ability to provide the exact materials and documentation required without necessitating the revalidation of established manufacturing processes.
General Info
Agency
NAICS
Place of Performance
Bethesda, MD, 20892, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Response Deadline
Organization & Contact Information
Full Description
NOTICE OF INTENT TO SOLE SOURCE
Thermo Fisher Scientific (Life Technologies)
Reagents and Consumable Materials for Cell Therapy Manufacturing
Agency
Department of Health and Human Services (HHS), National Institutes of Health (NIH), Clinical Center
Program Office
Center for Cellular Engineering (CCE), Department of Transfusion Medicine
Notice Type
Notice of Intent to Sole Source
Proposed Source
Thermo Fisher Scientific (Life Technologies)
Response Due
August 20, 2026 at 8:00 AM Eastern Time
DESCRIPTION
The National Institutes of Health (NIH), Clinical Center, Center for Cellular Engineering (CCE) intends to award a firm-fixed-price contract on a sole-source basis to Thermo Fisher Scientific (Life Technologies) for reagents and consumable materials used in the manufacture of cell-based therapies for patients enrolled in clinical trials at the NIH Clinical Center.
REQUIRED MATERIALS
Description/Part No./Quantity
AIM V MED CTS 1000ML/0870112DK/12 Bottles
DYNABEADS CD3/CD28 CTS 10 ML/40203D/3 Vials
CTS AIM-V MEDIUM MINUS 1000ML/A3830801/12 Each
ACK LYSING BUFFER 100ML/A1049201/20 Bottles
RPMI 1640 100ML/11875101/25 Bottles
CTS AIM-V MEDIUM MINUS 10L/A3830802/4 Each
SOLE-SOURCE RATIONALE
CCE manufactures cell-based therapies under FDA-regulated current Good Manufacturing Practice (cGMP) conditions. The required Thermo Fisher Scientific (Life Technologies) reagents and consumable materials have been validated for CCE's manufacturing processes and approved by the CCE Quality Assurance Department. Substitution of these materials would require extensive requalification and validation of manufacturing processes, resulting in additional cost, significant time delays, and potential delays to patient treatment. Thermo Fisher Scientific (Life Technologies) can provide the required materials and quantities in a timely manner with the supporting documentation necessary for use in an FDA-regulated manufacturing process.
The Government intends to proceed under the authority cited in the supporting justification, 41 U.S.C. 3304(a)(1), for an acquisition available from only one responsible source where no other supplies will satisfy the agency's requirements.
CAPABILITY STATEMENTS / RESPONSE INSTRUCTIONS
This notice is not a request for competitive quotations. However, all responsible sources that believe they can satisfy the Government's requirement may submit a written capability statement demonstrating their ability to provide the exact required materials, quantities, and supporting documentation without causing revalidation of CCE's established manufacturing processes. Responses must contain sufficient technical information for the Government to determine whether the respondent can meet the requirement. Please reference number 26-008602 when submitting capability statements and submit them by the due date to shasheshe.goolsby@nih.gov.
Responses are due no later than August 20, 2026 at 8:00 AM Eastern Time.
Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. The Government will not reimburse respondents for costs associated with preparing or submitting a response.
Interested parties should submit their capability statement through the point of contact identified in the SAM.gov notice. The response should reference this Notice of Intent and the Thermo Fisher Scientific (Life Technologies) CCE reagents and consumable materials requirement.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao
Same awarding agency